The increasing field of targeted treatment relies heavily on recombinant cytokine technology, and a thorough understanding of individual profiles is paramount for optimizing experimental design and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveals significant differences in their c